University of South Florida

The Scripps Research Institute

Fate Therapeutics, Inc.

Caroline Desponts

Sheng Ding

Saiyong Zhu

William Garrow Kerr

Yan Shi

Tongxiang Lin

Wenlin Li

John D Mendlein

David Robbins

Daniel D Shoemaker

David L Robbins

Hongyan Zhou

Lia Elena Perez

Dan Shoemaker

Joseph Wahle

John Ninos

Paul Grayson

Pratik Multani

The invention provides improved methods for cell therapy. In particular, the invention provides therapeutic compositions of enhanced hematopoietic stem and progenitor cells having improved engraftment and homing properties, and methods of making the therapeutic compositions. The invention further provides methods of improving the efficacy of hematopoietic stem and progenitor cell transplantation including transplanting the therapeutic composition to subjects in need of hematopoietic system reconstitution.

Enhanced stem cell composition

The present invention provides for identification and use of small molecules to induce pluripotency in mammalian cells as well as other methods of inducing pluripotency.

Combined chemical and genetic approaches for generation of induced pluripotent stem cells

Chemical approaches for generation of induced pluripotent stem cells

The invention concerns a method for increasing megakaryocyte and megakaryocyte progenitor numbers in vitro or in vivo by suppressing SH2-containing inositol-5-phosphatase (SHIP) function in megakaryocytes or megakaryocyte progenitors expressing the SHIP gene. SHIP function can be suppressed by administering an interfering RNA, or other SHIP inhibitor, to the megakaryocytes or megakaryocyte progenitors in vitro or in vivo.

SHIP-deficiency to increase megakaryocyte progenitor production

A method of increasing megakaryocytes and platelet numbers in a patient comprising the step of inhibiting SHIP expression, including SHIP's enzymatic activity and signaling functions, whereby normal blood clotting is induced.

The instant invention teaches the inhibition of SHIP expression, or function, for the increased efficacy of autologous stem cell transplants. In another embodiment, interference with SHIP function can be used to temporarily expand and mobilize the hematopoietic stem cell compartment to assist with leukapheresis, to promote hematopoietic recovery after myeloablation treatments, to deplete target stem cell clones (such a leukemic clones and other tumor stem cell types), and to deplete, or damage, the repopulating ability of the endogenous hematopoietic stem cell pool in order to allow transplanted hematopoietic stem cells to better home and engraft and to promote in vivo expansion and mobilization of other organ-specific stem cell populations (e.g., mesenchymal, mammary).

Inhibition of SHIP to enhance stem cell harvest and transplantation

Growing community of inventors

La Jolla, CA, United States of America

Caroline Desponts